StockData
ACHVNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

ACHIEVE LIFE SCIENCES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$6.61+0.23 (+3.53%)

Close on Oct 19, 2026

Market cap
$617.64M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 11, 2026After market close–––
Q1 FY2026
Ended Mar 31, 2026
May 12, 2026Before market open–$-0.19–
Q4 FY2025
Ended Dec 31, 2025
Mar 24, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025Before market open–$-0.28–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025Before market open–$-0.37–
Q1 FY2025
Ended Mar 31, 2025
May 13, 2025Before market open–––
Q4 FY2024
Ended Dec 31, 2024
Mar 11, 2025Before market open–$-0.36–
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024After market close–$-0.36–
Q2 FY2024
Ended Jun 30, 2024
Aug 13, 2024After market close–$-0.25–
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024After market close–$-0.26–
Q4 FY2023
Ended Dec 31, 2023
Mar 28, 2024After market close–$-0.26–

Press releases

Announcements Achieve Life Sciences filed with the SEC